Quarterly results · ZYDUSLIFE
ZYDUS LIFESCIENCES LTD reported revenue of ₹7,754 cr and net profit of ₹926 cr in Q2 FY27 (quarter ended 30 Sept 2026), -26.6% year on year. Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated when Yahoo Finance publishes updated financial statements; exchange filings can appear earlier.
| Quarter | Q2 FY27 |
|---|---|
| Quarter ended | 30 Sept 2026 |
| Revenue | ₹7,754 cr |
| Revenue YoY | — |
| Operating profit | ₹1,153 cr |
| Operating margin | 14.9% |
| Net profit | ₹926 cr |
| Net profit YoY | -26.6% |
| Net profit QoQ | -1.5% |
| Net margin | 11.9% |
| Basic EPS | ₹9.28 |
| TTM revenue | ₹29,771 cr |
| TTM net profit | ₹4,180 cr |
| TTM net margin | 14.0% |
ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) has reported its Q2 FY27 results for the quarter ended 2026-09-30. The company posted revenue of ₹7,754 cr and a net profit of ₹926 cr, translating into earnings per share of ₹9.28.
Compared with the same quarter a year earlier, revenue changed and net profit declined strongly by -26.6%.
Operating profit for the quarter stood at ₹1,153 cr, an operating margin of 14.9%.
Revenue
₹7,754 cr
— YoY
Net profit
₹926 cr
-26.6% YoY
Operating profit
₹1,153 cr
-11.4% YoY
EPS
₹9.28
-25.9% YoY
Swipe sideways to see all columns →
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q2 FY272026-09-30 | ₹7,754 cr | ₹1,153 cr | ₹926 cr | 14.9% | 11.9% | ₹9.28 | -26.6% | -1.5% |
| Q1 FY272026-06-30 | ₹7,802 cr | ₹1,318 cr | ₹940 cr | 16.9% | 12.0% | ₹9.35 | — | -26.1% |
| Q4 FY262026-03-31 | ₹7,434 cr | ₹1,401 cr | ₹1,273 cr | 18.8% | 17.1% | ₹12.65 | — | +22.1% |
| Q3 FY262025-12-31 | ₹6,780 cr | ₹1,292 cr | ₹1,042 cr | 19.1% | 15.4% | ₹10.36 | — | -17.4% |
| Q2 FY262025-09-30 | — | ₹1,301 cr | ₹1,261 cr | — | — | ₹12.53 | — | — |
| Q1 FY262025-06-30 | ₹6,467 cr | — | — | — | — | — | — | — |
| TTM (last 4 quarters) | ₹29,771 cr | ₹5,165 cr | ₹4,180 cr | 17.3% | 14.0% | ₹41.64 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q2 FY272026-09-30 | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|---|---|---|---|---|---|
| Revenue / Sales | ₹7,754 cr | ₹7,802 cr | ₹7,434 cr | ₹6,780 cr | — | ₹6,467 cr |
| Total expenses | ₹6,601 cr | ₹6,484 cr | ₹6,033 cr | ₹5,488 cr | ₹4,737 cr | — |
| Gross profit | ₹5,600 cr | ₹5,562 cr | ₹5,458 cr | ₹4,944 cr | — | ₹4,678 cr |
| Operating profit (EBIT) | ₹1,153 cr | ₹1,318 cr | ₹1,401 cr | ₹1,292 cr | ₹1,301 cr | — |
| Operating margin | 14.9% | 16.9% | 18.8% | 19.1% | — | — |
| Interest cost | ₹187 cr | ₹156 cr | ₹123 cr | ₹130 cr | — | ₹84.7 cr |
| Profit before tax | ₹1,262 cr | ₹1,307 cr | ₹1,660 cr | ₹1,353 cr | ₹1,694 cr | — |
| Tax expense | ₹334 cr | ₹354 cr | ₹318 cr | ₹388 cr | ₹453 cr | — |
| Effective tax rate | 26.5% | 27.1% | 19.2% | 28.7% | 26.8% | — |
| Net profit (PAT) | ₹926 cr | ₹940 cr | ₹1,273 cr | ₹1,042 cr | ₹1,261 cr | — |
| Net profit margin | 11.9% | 12.0% | 17.1% | 15.4% | — | — |
| Basic EPS | ₹9.28 | ₹9.35 | ₹12.65 | ₹10.36 | ₹12.53 | — |
| Diluted EPS | ₹9.28 | ₹9.35 | ₹12.65 | ₹10.36 | ₹12.53 | — |
| Growth | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|---|---|
| Revenue YoY | — | +20.6% | — | — | — | — |
| Revenue QoQ | -0.6% | +4.9% | +9.6% | — | — | — |
| Operating profit YoY | -11.4% | — | — | — | — | — |
| Operating profit QoQ | -12.5% | -5.9% | +8.4% | -0.7% | — | — |
| Net profit YoY | -26.6% | — | — | — | — | — |
| Net profit QoQ | -1.5% | -26.1% | +22.1% | -17.4% | — | — |
| EPS YoY | -25.9% | — | — | — | — | — |
| EPS QoQ | -0.7% | -26.1% | +22.1% | -17.3% | — | — |
Full-year performance for ZYDUS LIFESCIENCES LTD, useful for reading each quarter in context.
| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹26,720 cr | ₹22,574 cr | ₹19,022 cr | ₹16,878 cr |
| Total expenses | ₹20,933 cr | ₹16,595 cr | ₹14,482 cr | ₹14,025 cr |
| Gross profit | ₹19,061 cr | ₹15,907 cr | ₹12,521 cr | ₹10,319 cr |
| Operating profit (EBIT) | ₹5,787 cr | ₹5,979 cr | ₹4,539 cr | ₹2,853 cr |
| Operating margin | 21.7% | 26.5% | 23.9% | 16.9% |
| Interest cost | ₹365 cr | ₹93.5 cr | ₹44 cr | ₹126 cr |
| Profit before tax | ₹6,621 cr | ₹6,027 cr | ₹4,809 cr | ₹2,590 cr |
| Tax expense | ₹1,595 cr | ₹1,412 cr | ₹978 cr | ₹588 cr |
| Effective tax rate | 24.1% | 23.4% | 20.3% | 22.7% |
| Net profit (PAT) | ₹5,040 cr | ₹4,526 cr | ₹3,860 cr | ₹1,960 cr |
| Net profit margin | 18.9% | 20.0% | 20.3% | 11.6% |
| Basic EPS | ₹50.09 | ₹44.97 | ₹38.14 | ₹19.30 |
| Diluted EPS | ₹50.09 | ₹44.97 | ₹38.14 | ₹19.30 |
Topline for Q2 FY27 came in at ₹7,754 cr against — in Q2 FY26, and ₹7,802 cr in the preceding Q1 FY27 quarter.
On a sequential basis revenue declined -0.6%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹6,601 cr, or 85.1% of revenue, with operating profit declined -11.4% year on year.
Net profit of ₹926 cr works out to a net margin of 11.9%.
Below the operating line, ZYDUS LIFESCIENCES LTD reported profit before tax of ₹1,262 cr, a tax charge of ₹334 cr (effective rate 26.5%), interest cost of ₹187 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹940 cr in Q1 FY27 to ₹926 cr in Q2 FY27, a change of -1.5%.
Across the trailing four quarters ZYDUS LIFESCIENCES LTD has generated revenue of ₹29,771 cr and net profit of ₹4,180 cr, a trailing net margin of 14.0%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹26,720 cr with net profit of ₹5,040 cr and EPS of ₹50.09, versus the prior year where revenue grew +18.4% and profit grew +11.4%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
No next results date is available in the board-meeting calendar. Statement figures update when Yahoo Finance makes them available; this is not an immediate exchange-filing feed.
Financial figures here are supplied through Yahoo Finance fundamentals and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
Zydus Lifesciences (ZYDUSLIFE) trades at ₹1,178.80, -9.30 (-0.78%). The quarterly-results trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Zydus Lifesciences Limited Q2 FY27 consolidated results: revenue from operations of ₹7,910 cr and net profit of ₹928 cr.
| Board meeting date | Purpose | Details |
|---|---|---|
| 4 Nov 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
Zydus Lifesciences (ZYDUSLIFE) last traded at ₹1,139.00, -6.70 (-0.58%) as the in-focus story plays out. Last-session board, day range, twelve-month context and the follow-up that decides the next session.
Zydus Lifesciences (ZYDUSLIFE) last traded at ₹1,215.00, +11.10 (+0.92%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
Zydus Lifesciences (ZYDUSLIFE) last traded at ₹1,203.90, +23.60 (+1.96%). The in-focus trigger, the levels the tape is defending, and what the numbers mean for traders and long-term holders.
Zydus Lifesciences (ZYDUSLIFE) last traded at ₹1,203.90, +23.60 (+1.96%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
Zydus Lifesciences (ZYDUSLIFE) last traded at ₹1,170.10, +7.80 (+0.67%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
In Q2 FY27 (quarter ended 30 Sept 2026), ZYDUS LIFESCIENCES LTD reported revenue of ₹7,754 cr and net profit of ₹926 cr, a change of -26.6% year on year. EPS stood at ₹9.28.
ZYDUS LIFESCIENCES LTD posted a net profit margin of 11.9% and an operating margin of 14.9% in Q2 FY27. On a trailing twelve-month basis, revenue is ₹29,771 cr and net profit ₹4,180 cr.
ZYDUS LIFESCIENCES LTD net profit changed -1.5% quarter on quarter, from ₹940 cr in Q1 FY27 to ₹926 cr in Q2 FY27.
ZYDUS LIFESCIENCES LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Our latest ZYDUSLIFE results coverage — "Why Zydus Lifesciences Share Price Opens Gap-Up at ₹1,200.00 Today: the Quarterly Results Trigger, Explained" — breaks down revenue, profit, margins and management commentary.
For FY26, ZYDUS LIFESCIENCES LTD reported full-year revenue of ₹26,720 cr and net profit of ₹5,040 cr, with EPS of ₹50.09.
ZYDUSLIFE has held 1 recent board meetings for financial results, the last on 4 Nov 2026.
Results dates: NSE board-meeting calendar. Financial figures: Yahoo Finance fundamentals, not a direct exchange filing feed. Last successful data fetch 8 Nov 2026. Figures can be delayed; results change only when the provider publishes them. For information only, not investment advice.
